| Parameter | Sitagliptin | Teneligliptin |
| Drug Class | DPP-4 Inhibitor | DPP-4 Inhibitor |
| Used For | Type 2 Diabetes | Type 2 Diabetes |
| Usual Dose | 100 mg once daily | 20 mg once daily |
| Dose Adjustment (Kidney) | Required | Usually not required |
| Available Strength | 25 mg, 50 mg, 100 mg | 20 mg, 40 mg |
| Common Side Effects | Headache, cold symptoms, diarrhea | Constipation, nausea, dizziness |
| Risk of Hypoglycemia | Low | Low |
| Weight Gain | No | No |
| Long-term Data | More global studies available | Fewer long-term global studies |
| Cost | More affordable | affordable |
| Use in Kidney Patients | With dose adjustment | Preferred option |
| Dosing Frequency | Once daily | Once daily |
conclusion
Both Sitagliptin and Teneligliptin are used to treat type 2 diabetes and work in a similar way. Sitagliptin has more long-term safety data worldwide, while Teneligliptin is often preferred in patients with kidney problems and is usually more affordable. Both medicines have a low risk of hypoglycemia and are suitable for long-term diabetes treatment under doctor supervision.